• Appropriations for the National Breast and Cervical Cancer Early Detection Program Appropriations for breast cancer research Appropriations for cancer prevention and control Policies related to access to supplemental and diagnostic breast imaging FY24 House and Senate Labor-HHS Appropriations bills FY25 House and Senate Labor-HHS Appropriations bills Policies related to the transparent use of artificial intelligence, via patient notification, and validation of its use, scaling and outcomes in breast cancer screening.
• Access to Breast Cancer Diagnosis (ABCD) Act (H.R.3851/S. 2464) Cancer Drug Parity Act (S. 2039) Telehealth Benefit Expansion for Workers Act (H.R. 824) Association Health Plans Act (H.R. 2868) Safe Step Act (H.R.2630/S. 652) Implementation of the Affordable Care Act Policies related to insurance coverage and COVID-19 HELP Copays Act (H.R.830/S.1375) Cancer survivorship issues Issues related to prescription drug affordability for patients Administrative actions necessary to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging Congressional action to reduce out-of-pocket costs for medically necessary diagnostic breast imaging Issues related to regulation of short-term limited duration plans Implementation of the No Surprises Act, including comments on proposed rule re: Federal Independent Dispute Resolution Operations Find It Early Act (H.R.3086); a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals Policies related to coverage of preventive services with no cost-sharing Polices regarding White House Cancer Moonshot implementation Policies related to copay accumulator adjustors Comments related to the Mental Health Parity and Addiction Equity Act Letter to Committee on Education and the Workforce Request for Information on Employer-Sponsored Insurance and Employee Retirement Income Security Act (ERISA)
• Metastatic Breast Cancer Access to Care Act (S. 663 / HR 549) Reducing Hereditary Cancer Act (HR 1526/S. 765) CONNECT for Health Act (H.R. 4189/S. 2016) Medicare coverage policy for breast cancer treatments and services Telehealth Policies related to funding, state incentives, and federal efforts for Medicaid expansion Issues related to 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid Policies related to Medicare coverage for pharmacy services Medicare coverage policy for drugs and drug pricing H.R. 9505 - Find It Early Act; a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals Medicaid unwinding, the process for redetermination of Medicaid eligibility Medicare Drug Pricing Negotiation implementation Implementation of Lymphedema Treatment Act Preserving and expanding access to Medicaid Comments on Processes for Assessing Compliance with Mental Health Parity and Addiction Equity in Medicaid and CHIP Policy related to medical billing for breast reconstruction surgery called DIEP flap, a type of natural tissue breast reconstruction that uses non-breast tissue to replace breast tissue Community Health Worker Access Act which is a bill to amend titles XVIII and XIX of the Social Security Act to increase access to community health workers under the Medicare and Medicaid programs (S. 3892) Equitable Community Access to Pharmacist Services Act (S. 2477/H.R. 1770) Access to Genetic Counselor Services Act (H.R.3876/S.2323) Comments Re: Medicaid; CMS Enforcement of State Compliance with Reporting and Federal Medicaid Renewal Requirements Under Section 1902(t) of the Social Security Act (CMS-2447-IFC) Comments RE: Notice of Benefit and Payment Parameters for 2025 Proposed Rule (CMS-9895-P). Comments RE OIG Solicitation New and Modified Safe Harbors and Special Fraud Alerts OIG-1123-N, 88 Fed. Reg. 84116 requesting permission for sponsors of clinical trials targeting cancer or other life-threatening diseases or conditions to cover certain indirect costs incurred by clinical trial participants. Comments RE: Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025
• Health disparities Access to clinical trials for underrepresented populations Policies related to cancer survivorship Policies related to medications access in during emergencies Polices related to PBM and drug cost transparency Policies related to COVID-19 vaccination distribution Policies impacting immunocompromised people, including COVID-19 vaccination and monoclonal antibody distribution Policies related to reducing the cost of cancer treatment for patients Policies related to decline in breast cancer screenings during the COVID-19 pandemic Policies related to genetic counseling and screening Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 (H.R.3916/S.1840) Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017 and the 2023 Final Rule Amending Part 900 of the Mammography Quality Standards Act Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to the regulation of diagnostic devices, including comments on the proposed rule to regulate Medical Devices; Laboratory Developed Tests Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2021 or the BENEFIT Act of 2021, requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs (S.373/ H.R.4472) Palliative Care and Hospice Education Training Act (PCHETA) (S. 2243) The Patent Eligibility Restoration Act (S.2140) Policies related to ICD-10 code for inflammatory breast cancer
• H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act Outreach to the Dr. Bertagnolli, NIH Director, and the Office of the Director Outreach to the White House RE: Initiative on Women's Health Research

Duration: April 1, 2020 to present

General Issues: Budget/Appropriations, Insurance, Medicare/Medicaid, Health Issues, Medical/Disease Research/Clinical Labs, Defense, Veterans

Spending: about $652,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2020: U.S. Senate, House of Representatives, White House Office, Office of Science & Technology Policy (OSTP), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Internal Revenue Service (IRS), Labor - Dept of (DOL), Office of Personnel Management (OPM), Centers For Medicare and Medicaid Services (CMS), Treasury - Dept of, Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Centers For Disease Control & Prevention (CDC), President of the U.S., Federal Trade Commission (FTC)